Seeking Alpha
, IPOpremium (1,446 clicks)
Value, IPOs, long only
Profile| Send Message|
( followers)  

Summary

  • A development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases.
  • Price-to-book is 4.1. Low cash burn rate (P/e ratio of -144).
  • 25% of the IPO is spoken for.

Based in Tel Aviv, Israel, Bio Blast Pharma Ltd. (NASDAQ:ORPN) scheduled a $40 million IPO on the Nasdaq with a market capitalization of $172 million at a price range midpoint of $172 for Friday, Aug. 1, 2014.

The full IPO calendar is available at IPOpremium

SEC Documents

Manager, Co-Managers: Oppenheimer/ Roth Capital Partners

Joint Managers: BTIG

End of lockup (180 days): Wednesday, January 28, 2015

End of 25-day quiet period: Tuesday, August 26, 2014

Summary

ORPN is a development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases.

Valuation

Glossary

Valuation Ratios

Mrkt Cap ($mm)

Price /Sls

Price /Erngs

Price /BkVlue

Price /TanBV

% offered in IPO

2013 yr

      

Bio Blast Pharma Ltd.

$173

n/a

-144.0

4.1

4.1

23%

       

Conclusion

The rating is neutral

25% of the IPO is spoken for

Price-to-book is 4.1

Low cash burn rate (P/e ratio of -144)

Business

ORPN is a development-stage biopharmaceutical company focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases.

ORPN seeks to identify therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. ORPN focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood and for which there is no satisfactory treatment.

Since its inception in 2012, ORPN has developed and in-licensed potential treatments for six diseases, one of which in a Phase 2/3 clinical trial which, if the results are positive, ORPN believes could be a pivotal trial, another one which is in Phase 2 clinical study and an additional two of which ORPN expects will be in mid/late stage clinical studies by late 2014 or early 2015. ORPN has not yet submitted any investigational new drug applications for its products to the FDA.

ORPN's current drug candidate pipeline has been either in-licensed from academic institutions or developed internally.

ORPN's strategy is based on risk diversification through multiple therapeutic platforms, diversified clinical and pre-clinical stages of its programs, and diversified diseases addressed.

ORPN uses strict selection criteria of its pipeline platforms and cost-efficient drug development. This allows ORPN to pursue multiple programs in parallel with the goal of promptly delivering safe and effective therapies to patients in dire need.

Dividend Policy

No dividends are planned.

Intellectual Property

ORPN seeks patent protection in the United States and internationally for its product candidates and other technology.

ORPN's policy is to patent or in-license the technology, inventions and improvements that ORPN considers important to the development of its business.

In addition to patent protection, ORPN intends to use other means to protect its proprietary rights, including pursuing marketing or data exclusivity periods, orphan drug status, and similar rights that are available under regulatory provisions in certain countries, including the United States, Europe, Japan, and China.

Competition

The commercialization of new drugs is competitive, and ORPN may face worldwide competition from individual investigators, major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, nutraceutical companies, and ultimately biosimilar and generic companies.

The acquisition or licensing of pharmaceutical products is also very competitive, and a number of more established companies, which have acknowledged strategies to license or acquire products, may have competitive advantages as may other emerging companies taking similar or different approaches to product acquisitions.

These established companies may have a competitive advantage over ORPN due to their size, cash flows, and institutional experience.

5% stockholders

Udi Gilboa 29.8%

Dr. Dalia Megiddo 29.8%

Pontifax 20.2%

Use of proceeds

ORPN intends to use the $36 million in proceeds from its IPO as follows:

completing its clinical program for OPMD, estimated at $6,000,000;

completing its Phase 2 and pivotal clinical study for SCA3, estimated at $3,500,000;

Initiating and completing its Phase 2/3 clinical study for SBMA, estimated at $4,200,000;

completing its pre-clinical program for BB-FA and Phase 1 clinical study, estimated at $4,500,000;

completing its pre-clinical program for BB-OTC and initiation and completion of Phase 1 and 2A-2B clinical studies, estimated at $7,800,000;

Initiating and completing its Phase 1-2 clinical programs for SMA, estimated at $2,200,000;

Other Indications, estimated at $500,000;

Premarketing activity for OPMD, estimated at $1,500,000; and

the remainder for personnel-related costs, preclinical research, working capital, and other general corporate purposes.

Disclaimer: This ORPN IPO report is based on a reading and analysis of ORPN's S-1 filing, which can be found here, and a separate, independent analysis by IPOdesktop.com. There are no unattributed direct quotes in this article.

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it. The author has no business relationship with any company whose stock is mentioned in this article.

Source: IPO Preview: Bio Blast Pharma Ltd.